After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
Critical discussion of the cardiovascular findings with empagliflozin (EMPA-REG OUTCOME Study)and liraglutide (LEADER Study) and the consequences.